亞洲健康人群CYP2C19等位基因發生率的合并分析_《中國循證醫學雜志》

作者：

張愛玲 ^1,2 , 楊莉萍 ¹ ,  胡欣 ¹

1. 沈陽藥科大學藥學院（沈陽 110016）；2. 衛生部北京醫院藥學部（北京 100730;

關鍵詞：

CYP2C19 等位基因發生率亞洲

DOI：

10.7507/1672-2531.2013024

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　對亞洲人群CYP2C19等位基因發生率的相關文獻進行合并分析，為個體化藥物治療和藥物基因組學研究提供依據。
方法　計算機檢索PubMed、EMbase、Cochrane圖書館、CNKI、WanFang Data、VIP和CBM等數據庫，納入CYP2C19等位基因發生率的相關文獻。按照納入與排除標準篩選文獻、提取數據后進行合并分析。
結果　共納入41篇文獻，包含17個國家9841例健康亞洲人的CYP2C19等位基因的信息。按東亞（中國、韓國和日本）、東南亞（越南、泰國、馬來西亞、新加坡、緬甸、印度尼西亞和菲律賓）、南亞（印度）和西亞（巴勒斯坦、黎巴嫩、沙特阿拉伯、土耳其、伊朗和約旦）分區域進行分析，主要研究結果如下：CYP2C191、2和3等位基因的發生率，中國人群（n=4170）分別為61.3%、32.1%和6.6%；東亞人群（n=5879）分別為61.0%、31.2%和7.8%；東南亞人群（n=1985）分別為67.6%、28.8%和3.7%；南亞人群（n=679）分別為64.0%、35.2%和0.8%；西亞人群（n=1298）分別為87.3%、12.1% 和0.6%；亞洲以上四個地區17個國家9841例CYP2C191、2和3等位基因的總發生率分別為66.0%、28.4%和5.5%。
結論　CYP2C19各等位基因的發生率在我國及亞洲不同區域之間均存在較大差異（P lt;0.05），且遺傳變異也會受地域環境的影響。

引用本文： 張愛玲,楊莉萍,胡欣. 亞洲健康人群CYP2C19等位基因發生率的合并分析. 中國循證醫學雜志, 2013, 13(12): 1431-1439. doi: 10.7507/1672-2531.2013024 復制

1. Kim YM, Yoo SH, Kang RY, et al. Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. Am J Health Syst Pharm, 2007, 64(2): 166-175.

2. Available: http: //www.cypalleles.ki.se/CYP2C19.htm, http: //www.cypalleles.ki.se/.

3. PharmGKB. Variant in CYP2C19. Stanford University. 2012PharmGKB. Variant in CYP2C19. Stanford University; 2012 [cited 2013 Sep. 19]. Available from: https: //www.pharmgkb.org.

4. Sawada T, Shinke T, Shite J, et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J, 2011, 75(1): 99-105.

5. Tang, XF, Wang J, Zhang JH, et al. Effect of the CYP2C19*2 and *3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol, 2013, 69(5): 1103-1112.

6. 楊莉萍, 謝婧, 劉瑤, 等. CYP2C19*2、*3基因多態性與氯吡格雷臨床療效相關性的系統評價. 中國循證醫學雜志, 2012, (09): 1063-1070.

7. Kurose, K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet, 2012, 27(1): 9-54.

8. Fu LQ, Huang F, Wu DZ, et al. [Comparison of genetic polymorphism of cytochrome CYP2C19 between men and women in Chinese population]. Acta pharmaceutica Sinica, 2004, 39(3): 161-163.

9. Kadeer A, Anwar M, Chun-yan N, et al. Genetic polymorphism of cytochrome P450 2C19 in Xinjiang Uigur population versus Han population. Journal of Clinical Rehabilitative Tissue Engineering Research, 2010, 14(31): 5887-5889.

10. Wang SM, Zhu AP, Li D, et al. Frequencies of genotypes and alleles of the functional SNPs in CYP2C19 and CYP2E1 in mainland Chinese Kazakh, Uygur and Han populations. J Hum Genet, 2009, 54(6): 372-375.

11. Yin SJ, Ni YB, Wang SM, et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther, 2012, 37(3): 364-369.

12. Zhou SX, Xie HG, Wang W, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther, 1997, 281(1): 604-609.

13. Zuo J, Xia D, Jia L, et al. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. Pharmazie, 2012, 67(7): 639-644.

14. 郭志強. 基于 CYP 多態性的氯吡格雷-質子泵抑制劑相互作用研究. 西安: 第四軍醫大學, 2010.

15. 胡玉榮. 蘭索拉唑在國人不同基因型個體內的藥動學. 鄭州: 鄭州大學, 2003.

16. 邵華, 劉乃豐, 周東蕊, 等. 雙色熒光雜交芯片技術檢測CYP2C19單核苷酸多態性. 中國新藥與臨床雜志, 2009, 28(4): 249-253.

17. 閆春蘭, 詹金彪, 陳樞青. 浙江省漢族與畬族CYP2C19基因多態性研究. 中國藥學雜志, 2004, (11): 70-72.

18. 周健, 呂虹, 康熙雄. 中國漢族人群不同性別、年齡、體重指數之間細胞色素氧化酶CYP2C19基因多態性的檢測. 中國臨床藥理學與治療學, 2007, (02): 208-213.

19. Zhou HH. Genetic polymorphism of CYP2C19 in Chinese ethnic populations. International Congress Series, 2002, 1244: 51-61.

20. Wang JH, Li PQ, Fu QY, et al. CYP2C19 genotype and omeprazole hydroxylation phenotype in Chinese Li population. Clinical and experimental pharmacology & physiology, 2007, 34(5-6): 421-424. Clin Exp Pharmacol Physiol, 2007, 34(5-6): 421-424.

21. 李永芳, 楊梅, 寇毅英. 青海撒拉族人群CYP2C19基因多態性研究. 中國藥學雜志, 2012, 47(07): 539-42.

22. He N, Yan FX, Huang SL, et al. CYP2C19 genotype and S-mephenytoin 4’-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol, 2002, 58(1): 15-18.

23. Yin SJ, Ni YB, Wang SM, et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther, 2012, 37(3): 364-369.

24. 陳華芳. 細胞色素CYP2C19 (P4502C19) 基因多態性與食管癌易感性的關系. 福州: 福建醫科大學, 2006.

25. 張林. CYP2C19基因多態性分析及其與奧美拉唑療效關系的臨床研究. 吉林: 吉林大學, 2004.

26. Kimura M, Ieiri I, Mamiya K, et al. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit, 1998, 20(3): 243-247.

27. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4’-hydroxylation in an extended Japanese population. Clin Pharmacol Ther, 1996, 60(6): 661-666.

28. Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol, 2010, 50(8): 929-940.

29. Perini JA, Vargens DD, Santana IS, et al. Pharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants. Braz J Med Biol Res, 2009, 42(12): 1179-1184.

30. Tsuneoka Y, Fukushima K, Matsuo Y, et al. Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sci, 1996, 59(20): 1711-1715.

31. Lee SS, Lee SJ, Gwak J, et al. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther Drug Monit, 2007, 29(4): 455-459.

32. Roh HK, Dahl ML, Tybring G, et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics, 1996, 6(6): 547-551.

33. Veiga MI, Asimus S, Ferreira PE, et al. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol, 2009, 65(4): 355-363.

34. Tassaneeyakul W, TATawalee A, Tassaneeyakul W, et al. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. Pharmacogenetics, 2002, 12(3): 221-225.

35. Tassaneeyakul W, Mahatthanatrakul W, Niwatananun K, et al. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab Pharmacokinet, 2006, 21(4): 286-290.

36. Yang Y S, Wong LP, Lee T C, et al. Genetic polymorphism of cytochrome P4502C19 in healthy Malaysian subjects. Br J Clin Pharmacol, 2004, 58(3): 332-35.

37. Rusdiana, T, Araki T, Nakamura T, et al. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Eur J Clin Pharmacol, 2013, 69(3): 395-405.

38. Goldstein, JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 1997, 7(1): 59-64.

39. Jose R, Chandrasekaran A, Sam SS, et al. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam Clin Pharmacol, 2005, 19(1): 101-105.

40. Lamba JK, Dhiman RK, Kohli KK. CYP2C19 genetic mutations in North Indianss&ast. Clin Pharmacol Ther, 2000, 68(3): 328-335.

41. Ghodke Y, Joshi K, Arya Y, et al. Genetic polymorphism of CYP2C19 in Maharashtrian population. Eur J Epidemiol, 2007, 22(12): 907-915.

42. Satyanarayana CRU, Devendran A, Sundaram R, et al. Genetic variations and haplotypes of the 5’-regulatory region of CYP2C19 in South Indian population. Drug Metab Pharmacokinet, 2009, 24(2): 185-193.

43. Sameer AE, Amany GM, Abdela AA, et al. CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip. Can J Clin Pharmacol, 2009, 16(1): e156-162.

44. Djaffar Jureidini I, Chamseddine N, Keleshian S, et al. Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep, 2011, 38(8): 5449-5452.

45. Aynacioglu AS, Sachse C, Bozkurt A, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population&ast. Clin Pharmacol Ther, 1999, 66(2): 185-192.

46. Zand N, Tajik N, Moghaddam AS, et al. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol, 2007, 34(1-2): 102-105.

47. Yousef AM, Bulatova NR, Newman W, et al. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol Biol Rep, 2012, 39(10): 9423-9433.

48. Zalloum I, Hakooz N, Arafat T. Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. Mol Biol Rep, 2012, 39(4): 4195-4200.

49. Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4’-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics, 1999, 9(5): 539-549.

50. Xie HG, Kim RB, Stein CM, et al. Genetic polymorphism of (S)-mephenytoin 4’-hydroxylation in populations of African descent. Br J Clin Pharmacol, 1999, 48(3): 402-408.

1. Kim YM, Yoo SH, Kang RY, et al. Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. Am J Health Syst Pharm, 2007, 64(2): 166-175.

2. Available: http: //www.cypalleles.ki.se/CYP2C19.htm, http: //www.cypalleles.ki.se/.

3. PharmGKB. Variant in CYP2C19. Stanford University. 2012PharmGKB. Variant in CYP2C19. Stanford University; 2012 [cited 2013 Sep. 19]. Available from: https: //www.pharmgkb.org.

4. Sawada T, Shinke T, Shite J, et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J, 2011, 75(1): 99-105.

5. Tang, XF, Wang J, Zhang JH, et al. Effect of the CYP2C19*2 and *3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol, 2013, 69(5): 1103-1112.

6. 楊莉萍, 謝婧, 劉瑤, 等. CYP2C19*2、*3基因多態性與氯吡格雷臨床療效相關性的系統評價. 中國循證醫學雜志, 2012, (09): 1063-1070.

7. Kurose, K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet, 2012, 27(1): 9-54.

8. Fu LQ, Huang F, Wu DZ, et al. [Comparison of genetic polymorphism of cytochrome CYP2C19 between men and women in Chinese population]. Acta pharmaceutica Sinica, 2004, 39(3): 161-163.

9. Kadeer A, Anwar M, Chun-yan N, et al. Genetic polymorphism of cytochrome P450 2C19 in Xinjiang Uigur population versus Han population. Journal of Clinical Rehabilitative Tissue Engineering Research, 2010, 14(31): 5887-5889.

10. Wang SM, Zhu AP, Li D, et al. Frequencies of genotypes and alleles of the functional SNPs in CYP2C19 and CYP2E1 in mainland Chinese Kazakh, Uygur and Han populations. J Hum Genet, 2009, 54(6): 372-375.

11. Yin SJ, Ni YB, Wang SM, et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther, 2012, 37(3): 364-369.

12. Zhou SX, Xie HG, Wang W, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther, 1997, 281(1): 604-609.

13. Zuo J, Xia D, Jia L, et al. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. Pharmazie, 2012, 67(7): 639-644.

14. 郭志強. 基于 CYP 多態性的氯吡格雷-質子泵抑制劑相互作用研究. 西安: 第四軍醫大學, 2010.

15. 胡玉榮. 蘭索拉唑在國人不同基因型個體內的藥動學. 鄭州: 鄭州大學, 2003.

16. 邵華, 劉乃豐, 周東蕊, 等. 雙色熒光雜交芯片技術檢測CYP2C19單核苷酸多態性. 中國新藥與臨床雜志, 2009, 28(4): 249-253.

17. 閆春蘭, 詹金彪, 陳樞青. 浙江省漢族與畬族CYP2C19基因多態性研究. 中國藥學雜志, 2004, (11): 70-72.

18. 周健, 呂虹, 康熙雄. 中國漢族人群不同性別、年齡、體重指數之間細胞色素氧化酶CYP2C19基因多態性的檢測. 中國臨床藥理學與治療學, 2007, (02): 208-213.

19. Zhou HH. Genetic polymorphism of CYP2C19 in Chinese ethnic populations. International Congress Series, 2002, 1244: 51-61.

20. Wang JH, Li PQ, Fu QY, et al. CYP2C19 genotype and omeprazole hydroxylation phenotype in Chinese Li population. Clinical and experimental pharmacology & physiology, 2007, 34(5-6): 421-424. Clin Exp Pharmacol Physiol, 2007, 34(5-6): 421-424.

21. 李永芳, 楊梅, 寇毅英. 青海撒拉族人群CYP2C19基因多態性研究. 中國藥學雜志, 2012, 47(07): 539-42.

22. He N, Yan FX, Huang SL, et al. CYP2C19 genotype and S-mephenytoin 4’-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol, 2002, 58(1): 15-18.

23. Yin SJ, Ni YB, Wang SM, et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther, 2012, 37(3): 364-369.

24. 陳華芳. 細胞色素CYP2C19 (P4502C19) 基因多態性與食管癌易感性的關系. 福州: 福建醫科大學, 2006.

25. 張林. CYP2C19基因多態性分析及其與奧美拉唑療效關系的臨床研究. 吉林: 吉林大學, 2004.

26. Kimura M, Ieiri I, Mamiya K, et al. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit, 1998, 20(3): 243-247.

27. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4’-hydroxylation in an extended Japanese population. Clin Pharmacol Ther, 1996, 60(6): 661-666.

28. Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol, 2010, 50(8): 929-940.

29. Perini JA, Vargens DD, Santana IS, et al. Pharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants. Braz J Med Biol Res, 2009, 42(12): 1179-1184.

30. Tsuneoka Y, Fukushima K, Matsuo Y, et al. Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sci, 1996, 59(20): 1711-1715.

31. Lee SS, Lee SJ, Gwak J, et al. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther Drug Monit, 2007, 29(4): 455-459.

32. Roh HK, Dahl ML, Tybring G, et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics, 1996, 6(6): 547-551.

33. Veiga MI, Asimus S, Ferreira PE, et al. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol, 2009, 65(4): 355-363.

34. Tassaneeyakul W, TATawalee A, Tassaneeyakul W, et al. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. Pharmacogenetics, 2002, 12(3): 221-225.

35. Tassaneeyakul W, Mahatthanatrakul W, Niwatananun K, et al. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab Pharmacokinet, 2006, 21(4): 286-290.

36. Yang Y S, Wong LP, Lee T C, et al. Genetic polymorphism of cytochrome P4502C19 in healthy Malaysian subjects. Br J Clin Pharmacol, 2004, 58(3): 332-35.

37. Rusdiana, T, Araki T, Nakamura T, et al. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Eur J Clin Pharmacol, 2013, 69(3): 395-405.

38. Goldstein, JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 1997, 7(1): 59-64.

39. Jose R, Chandrasekaran A, Sam SS, et al. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam Clin Pharmacol, 2005, 19(1): 101-105.

40. Lamba JK, Dhiman RK, Kohli KK. CYP2C19 genetic mutations in North Indianss&ast. Clin Pharmacol Ther, 2000, 68(3): 328-335.

41. Ghodke Y, Joshi K, Arya Y, et al. Genetic polymorphism of CYP2C19 in Maharashtrian population. Eur J Epidemiol, 2007, 22(12): 907-915.

42. Satyanarayana CRU, Devendran A, Sundaram R, et al. Genetic variations and haplotypes of the 5’-regulatory region of CYP2C19 in South Indian population. Drug Metab Pharmacokinet, 2009, 24(2): 185-193.

43. Sameer AE, Amany GM, Abdela AA, et al. CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip. Can J Clin Pharmacol, 2009, 16(1): e156-162.

44. Djaffar Jureidini I, Chamseddine N, Keleshian S, et al. Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep, 2011, 38(8): 5449-5452.

45. Aynacioglu AS, Sachse C, Bozkurt A, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population&ast. Clin Pharmacol Ther, 1999, 66(2): 185-192.

46. Zand N, Tajik N, Moghaddam AS, et al. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol, 2007, 34(1-2): 102-105.

47. Yousef AM, Bulatova NR, Newman W, et al. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol Biol Rep, 2012, 39(10): 9423-9433.

48. Zalloum I, Hakooz N, Arafat T. Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. Mol Biol Rep, 2012, 39(4): 4195-4200.

49. Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4’-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics, 1999, 9(5): 539-549.

50. Xie HG, Kim RB, Stein CM, et al. Genetic polymorphism of (S)-mephenytoin 4’-hydroxylation in populations of African descent. Br J Clin Pharmacol, 1999, 48(3): 402-408.

上一篇
硒與大骨節病相關性的Meta分析

下一篇
CYP3A5基因型與腎移植患者他克莫司血藥濃度關系的系統評價

1資料與方法

1.1一般資料

1.2方法

1.3察指標和判定標準

1.4統計學方法

2結果

2.1兩組患者療效比較

2.2兩組患者換藥次數、導管留置時間、治愈時間比較

2.3兩組患者治療前后血清PCT、CRP、WBC水平比較

3討論

《中國循證醫學雜志》

亞洲健康人群CYP2C19等位基因發生率的合并分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

1.	Kim YM, Yoo SH, Kang RY, et al. Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. Am J Health Syst Pharm, 2007, 64(2): 166-175.
2.	Available: http: //www.cypalleles.ki.se/CYP2C19.htm, http: //www.cypalleles.ki.se/.
3.	PharmGKB. Variant in CYP2C19. Stanford University. 2012PharmGKB. Variant in CYP2C19. Stanford University; 2012 [cited 2013 Sep. 19]. Available from: https: //www.pharmgkb.org.
4.	Sawada T, Shinke T, Shite J, et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J, 2011, 75(1): 99-105.
5.	Tang, XF, Wang J, Zhang JH, et al. Effect of the CYP2C192 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol, 2013, 69(5): 1103-1112.
6.	楊莉萍, 謝婧, 劉瑤, 等. CYP2C192、3基因多態性與氯吡格雷臨床療效相關性的系統評價. 中國循證醫學雜志, 2012, (09): 1063-1070.
7.	Kurose, K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet, 2012, 27(1): 9-54.
8.	Fu LQ, Huang F, Wu DZ, et al. [Comparison of genetic polymorphism of cytochrome CYP2C19 between men and women in Chinese population]. Acta pharmaceutica Sinica, 2004, 39(3): 161-163.
9.	Kadeer A, Anwar M, Chun-yan N, et al. Genetic polymorphism of cytochrome P450 2C19 in Xinjiang Uigur population versus Han population. Journal of Clinical Rehabilitative Tissue Engineering Research, 2010, 14(31): 5887-5889.
10.	Wang SM, Zhu AP, Li D, et al. Frequencies of genotypes and alleles of the functional SNPs in CYP2C19 and CYP2E1 in mainland Chinese Kazakh, Uygur and Han populations. J Hum Genet, 2009, 54(6): 372-375.
11.	Yin SJ, Ni YB, Wang SM, et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther, 2012, 37(3): 364-369.
12.	Zhou SX, Xie HG, Wang W, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther, 1997, 281(1): 604-609.
13.	Zuo J, Xia D, Jia L, et al. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. Pharmazie, 2012, 67(7): 639-644.
14.	郭志強. 基于 CYP 多態性的氯吡格雷-質子泵抑制劑相互作用研究. 西安: 第四軍醫大學, 2010.
15.	胡玉榮. 蘭索拉唑在國人不同基因型個體內的藥動學. 鄭州: 鄭州大學, 2003.
16.	邵華, 劉乃豐, 周東蕊, 等. 雙色熒光雜交芯片技術檢測CYP2C19單核苷酸多態性. 中國新藥與臨床雜志, 2009, 28(4): 249-253.
17.	閆春蘭, 詹金彪, 陳樞青. 浙江省漢族與畬族CYP2C19基因多態性研究. 中國藥學雜志, 2004, (11): 70-72.
18.	周健, 呂虹, 康熙雄. 中國漢族人群不同性別、年齡、體重指數之間細胞色素氧化酶CYP2C19基因多態性的檢測. 中國臨床藥理學與治療學, 2007, (02): 208-213.
19.	Zhou HH. Genetic polymorphism of CYP2C19 in Chinese ethnic populations. International Congress Series, 2002, 1244: 51-61.
20.	Wang JH, Li PQ, Fu QY, et al. CYP2C19 genotype and omeprazole hydroxylation phenotype in Chinese Li population. Clinical and experimental pharmacology & physiology, 2007, 34(5-6): 421-424. Clin Exp Pharmacol Physiol, 2007, 34(5-6): 421-424.
21.	李永芳, 楊梅, 寇毅英. 青海撒拉族人群CYP2C19基因多態性研究. 中國藥學雜志, 2012, 47(07): 539-42.
22.	He N, Yan FX, Huang SL, et al. CYP2C19 genotype and S-mephenytoin 4’-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol, 2002, 58(1): 15-18.
23.	Yin SJ, Ni YB, Wang SM, et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther, 2012, 37(3): 364-369.
24.	陳華芳. 細胞色素CYP2C19 (P4502C19) 基因多態性與食管癌易感性的關系. 福州: 福建醫科大學, 2006.
25.	張林. CYP2C19基因多態性分析及其與奧美拉唑療效關系的臨床研究. 吉林: 吉林大學, 2004.
26.	Kimura M, Ieiri I, Mamiya K, et al. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit, 1998, 20(3): 243-247.
27.	Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4’-hydroxylation in an extended Japanese population. Clin Pharmacol Ther, 1996, 60(6): 661-666.
28.	Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol, 2010, 50(8): 929-940.
29.	Perini JA, Vargens DD, Santana IS, et al. Pharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants. Braz J Med Biol Res, 2009, 42(12): 1179-1184.
30.	Tsuneoka Y, Fukushima K, Matsuo Y, et al. Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sci, 1996, 59(20): 1711-1715.
31.	Lee SS, Lee SJ, Gwak J, et al. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther Drug Monit, 2007, 29(4): 455-459.
32.	Roh HK, Dahl ML, Tybring G, et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics, 1996, 6(6): 547-551.
33.	Veiga MI, Asimus S, Ferreira PE, et al. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol, 2009, 65(4): 355-363.
34.	Tassaneeyakul W, TATawalee A, Tassaneeyakul W, et al. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. Pharmacogenetics, 2002, 12(3): 221-225.
35.	Tassaneeyakul W, Mahatthanatrakul W, Niwatananun K, et al. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab Pharmacokinet, 2006, 21(4): 286-290.
36.	Yang Y S, Wong LP, Lee T C, et al. Genetic polymorphism of cytochrome P4502C19 in healthy Malaysian subjects. Br J Clin Pharmacol, 2004, 58(3): 332-35.
37.	Rusdiana, T, Araki T, Nakamura T, et al. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Eur J Clin Pharmacol, 2013, 69(3): 395-405.
38.	Goldstein, JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 1997, 7(1): 59-64.
39.	Jose R, Chandrasekaran A, Sam SS, et al. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam Clin Pharmacol, 2005, 19(1): 101-105.
40.	Lamba JK, Dhiman RK, Kohli KK. CYP2C19 genetic mutations in North Indianss&ast. Clin Pharmacol Ther, 2000, 68(3): 328-335.
41.	Ghodke Y, Joshi K, Arya Y, et al. Genetic polymorphism of CYP2C19 in Maharashtrian population. Eur J Epidemiol, 2007, 22(12): 907-915.
42.	Satyanarayana CRU, Devendran A, Sundaram R, et al. Genetic variations and haplotypes of the 5’-regulatory region of CYP2C19 in South Indian population. Drug Metab Pharmacokinet, 2009, 24(2): 185-193.
43.	Sameer AE, Amany GM, Abdela AA, et al. CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip. Can J Clin Pharmacol, 2009, 16(1): e156-162.
44.	Djaffar Jureidini I, Chamseddine N, Keleshian S, et al. Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep, 2011, 38(8): 5449-5452.
45.	Aynacioglu AS, Sachse C, Bozkurt A, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population&ast. Clin Pharmacol Ther, 1999, 66(2): 185-192.
46.	Zand N, Tajik N, Moghaddam AS, et al. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol, 2007, 34(1-2): 102-105.
47.	Yousef AM, Bulatova NR, Newman W, et al. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol Biol Rep, 2012, 39(10): 9423-9433.
48.	Zalloum I, Hakooz N, Arafat T. Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C191 and CYP2C192 on the pharmacokinetic profile of lansoprazole. Mol Biol Rep, 2012, 39(4): 4195-4200.
49.	Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4’-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics, 1999, 9(5): 539-549.
50.	Xie HG, Kim RB, Stein CM, et al. Genetic polymorphism of (S)-mephenytoin 4’-hydroxylation in populations of African descent. Br J Clin Pharmacol, 1999, 48(3): 402-408.

《中國循證醫學雜志》

亞洲健康人群CYP2C19等位基因發生率的合并分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料